Director Biostats Real World Evidence at Bristol-Myers Squibb

Madison, New Jersey, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceutical, Biotechnology, HealthcareIndustries

Requirements

PhD with 9+ years’ experience or MS with 11+ years’ experience
Deep expertise in working with RWD (e.g., claims, EMR, registries)
Expertise in RWE and clinical trials experience
Advanced RWD/causal inference methodologies
Strong analytical capabilities
Strong communication capabilities
Collaborative mindset

Responsibilities

Independently leads, initiates, and oversees the statistical support of RWE studies, including the development of methodologies, data analysis, interpretation, and reporting of study results
Independently lead curation and assessment of the quality of RWD assets to ensure their suitability and understanding for intended use
Lead the design and implementation of data pipelines to transform raw RWD into datasets ready for analysis
Lead and oversee exploratory data analyses, identify patient cohorts, and perform data summary analytics to support real-world evidence (RWE) generation
Continually expand technical knowledge of statistical considerations in real-world evidence generation to ensure high-quality study design and analysis
Collaborate with cross-functional teams—including TA-Biostatistics, Data Science, HEOR, Epidemiology/Safety, Clinical, and IT—to define data requirements and analytical strategies
Ensure all work complies with data governance, privacy, and regulatory standards
Stay up to date with industry and regulatory trends, tools, and best practices in RWD/RWE analytics
Enhance understanding of the drug development process, as well as regulatory and commercial requirements
Represents BMS at professional societies, and in industry-wide technical discussions
Contributes to the statistical community of practice
Provides active coaching to RWE team members when developing solutions to problems
Enables a culture of inclusiveness, respect for diversity, and compliance with process

Skills

Biostatistics

Real World Evidence

RWE

Statistical Methodologies

Study Design

Real-World Data

Healthcare Datasets

Data Curation

Data Transformation

Data Analysis

Evidence Generation

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free